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1. Supplementary Text: 
ST1. SCBC fabrication and operation:  
Antibody microarray which is used to quantify the protein concentration at single cell level is based 
on a DNA encoded antibody technology.
[1, 2]
 Antibody microarray comprises of spatially distinct array 
of single stranded DNA, which is flow-patterned on an poly-l-lysine glass substrate using high-density 
PDMS template (details in Supporting Information ST3 and ST4). Antibody array is prepared by 
hybridizing the antibody-DNA conjugate, just prior to cell loading and lysis process. The microarray 
has the capability of multiplexed measurement up to twenty different proteins. Details of the 
microarray fabrication is detailed in Supporting Information ST3. 
SCBC device which encapsulates and quantifies the protein concentration at single cell level is based 
on two-layer soft lithography (details in Supporting Information ST4). The two layer PDMS device was 
fabricated as described elsewhere 
[1, 2]
. The protocol for fabrication and operation of the SCBC device 
is based on previously published work,
[2]
 however with several modification to suite the cell handling 
and loading of the present system in consideration (detailed protocol in Supporting Information ST5). 
The SCBC assay measurements were calibrated to yield absolute protein copy numbers (Supporting 
Information ST6 and ST7). 
ST2. DEAL conjugate synthesis:  
Detailed protocol for the DNA-Antibody conjugation can found in Protein-Oligo conjugation kit 
(Solulink). Capture antibodies are desalted and buffer exchanged to pH 7.4 using Zeba protein 
desalting column (Pierce). Succinimidyl 4-hydrazinonicotinate acetone hydrazine (SANH, Solulink) is 
mixed in N,N dimethylformamide (DMF) was added to the desalted antibody solution in molar 
excess; (300:1 of SANH to antibody). Separately, succinimidyl 4- formylbenzoate (SFB) is mixed with 
DMF and was added to 5’-aminated oligomer in PBS in a molar excess of 16-fold (16:1; of SFB to 
DNA). These are allowed to react separately for 4 hrs at room temperature. Excess unreacted SANH 
and SFB are removed from both the samples and they are buffer-exchanged with Zeba desalting 
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column to pH 6.0 using citrate buffer. The DNA and antibody was combined and allowed to react 
overnight to form the conjugate. Non-reacted DNA and antibody is excluded using Pharmacia 200 gel 
filtration column (GE). The conjugates were then concentrated to ~0.5 mg/ml using Amicon Ultra-4 
centrifugal filter units (Millipore 10kDa) and kept for long-term storage at 4
0
C. 
ST3. DNA barcode fabrication:  
Fabrication of the Barcode slides have been described in extensive details elsewhere.
[1, 2]
 Here, only 
modifications of that protocol are highlighted. A polydimethyl siloxane (PDMS) elastomer substrate is 
prepared by mixing the base elastomer of SYLGARD® 184 Silicone with the binding agent in a mixing 
ratio of 10:1. A flow patterning silicon mold is used to produce a PDMS microfluidic layer for flow 
patterning the barcodes onto polylysine glass slides (VWR). The patterning PDMS substrate 
comprises of 20 parallel channels. For the present work only 12 channels were utilized.  The initial 
patterns are of unique ssDNA oligomers. After flow patterning is complete, the flow patterning PDMS 
layer is removed from the glass substrate, which can then be mated to separate PDMS layers to form 
the SCBC.  Of the 12 channels, 11 of them were used for the protein quantification and one was used 
as the reference marker (see Supplementary Table S1 for a list of all ssDNA and antibody reagents 
used). 
ST4. SCBC Fabrication:   
The PDMS integrated microfluidic chip for the single cell experiments were fabricated using two-layer 
soft lithography. Details of SCBC fabrication and operation have been previously published.
[2]
 A 
change in the published protocol was that both the control and the flow layer were fabricated using 
SYLGARD® 184 Silicone elastomer. The control layer and the flow layer were initially molded 
separately using an elastomer mix of 7:1 (A:B) and 20:1 (A:B), respectively. Thin flow layer is made by 
spin coating the PDMS mix over the silicon wafer at a speed of 2000 rpm for 60 seconds. Both the 
layers are cured separately at 80
0
C for 15 minutes. After curing, individual PDMS substrates are 
cooled to room temperature, and the control substrate was cut out and aligned with the flow layer. 
The aligned PDMS substrates were further cured at 80
o
C for 75 minutes. This curing ensured strong 
boding between the control and flow layers. The bonded PDMS substrate was then peeled off the 
surface of the silicon mold, and holes were punched for input and output access. Finally, the DNA 
barcoded poly-lysine slide is properly aligned and thermally bonded to the PDMS chip at 80
0
C for 2 
hours to produce an assembled device. The device is designed so that each of ~300 microchambers 
within a given SCBC contains a full 12-element barcode array. 
ST5. SCBC Operational details:  
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The protocols for using the SCBC device for profiling the intracellular proteins from single cells are 
described below: 
• The microfluidic channels are blocked with 1.5% BSA solution for one hour to reduce non-
specific binding.  
• Just prior to use, the ssDNA barcoded slide is converted to a capture antibody microarray 
through the DEAL technique, in which a cocktail of 11 antibody-ssDNA’ conjugates are flowed 
over the DNA patterned poly-lysine slide for 60 minutes at 37
0
C. Simultaneously, 
concentrated cell-lysis buffer with protease and phosphatase inhibitors were loaded to lysis 
buffer channel (channel 2 in  Figure S1b). The flow channel (channel 1 in Figure S1b) and the 
lysis buffer channel (channel 2 in Figure S1b) are isolated by control valve 4 (5 in Figure S1b), 
which is operated under 18 psi of pneumatic pressure. In order to remove the unconjugated 
DNA-antibody conjugates and to introduce physiological condition before loading the MCF-
10F cells, the micro channels were flushed with the complete growth medium for 10 
minutes.  
• MCF-10F cell samples are serum starved for 24 hours prior to loading into the SCBC device. 
MCF-10F cells are trypsinized using 0.05% Trypsin-EDTA solution. When the cells are about to 
detach (attain circular shape), the activity of Trypsin-EDTA is diluted with the solution of 
excess serum starved medium. The cells are pelleted by centrifuging the cell suspension at 
200g for 5 minutes. Prior to loading, cells were activated by suspending the pellet in serum 
starved medium dosed with 100 ng/ml of EGF and 100 ng/ml of Insulin and cell density in the 
medium is maintained ~1000 cells/ml. Within 30 minutes of growth factor treatment, the 
cells are loaded into the cell chambers and subsequently lysed. After loading the cells into 
the microchannels, valve 3 (6 in Figure S1b) is closed to compartmentalize the channels into 
310 micro chambers. Images of each chamber were recorded using a CCD camera and used 
for tabulating cell count per micro chamber. 
• The SCBC chip is placed on ice and a the separating valve (5 in Figure S1b) is opened to allow 
the lysis buffer to diffuse from lysis channel (2 in Figure S1b) to the cell chambers (1 in Figure 
S1b). The valve is opened for ~20 minutes to allow complete diffusion of lysis buffer into the 
microchamber. After which, the valve is closed and the SCBC chip is incubated on ice for ~40 
mins for complete cell lysis and diffusion. The chip was further incubated at room 
temperature for 2 hours to complete the capture of specific intracellular proteins onto the 
antibody barcode microarray within the respective microchambers. After the incubation, 
unbound cell-lysate and debris is flushed out using flowing 1.5% BSA solution for 10 minutes. 
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• A mixture of biotinylated-antibodies is prepared by mixing the antibodies at recommended 
ELISA concentration in 1.5% BSA solution. The detection antibody was flown through the 
channel for 60 minutes at room temperature to complete the immune-sandwich assay. 
Unbound detection antibody was flushed out of the SCBC device by washing the entire 
device with 1.5% BSA solution for 10 minutes. 
• Streptavidin-Cy5 (eBioscience, conc: 2µg/ml) and marker reference, Cy3-labelled 
complementary ssDNA (M-M’ at conc: 25nM) was prepared in 1.5% BSA solution and was 
flown through the channels for 60 minutes at room temperature. Unbound labels are flushed 
out of the system by washing the microchannels with 1.5% BSA for ~45 minutes. 
• After washing, the PDMS substrate is peeled of the glass surface and surface of the glass slide 
is washed by sequentially dipping the slide in 0.5X PBS, deionized water and finally dried 
under the flowing N2 stream.  
• Optical readout: The slide was scanned by an Axon GenePix 4400A (Molecular Devices) at the 
laser power of 80% (635 nm) and 10% (532 nm) and at a resolution of 2.5 μm. Average 
fluorescence readout from all the cell chambers were further extracted using a custom built 
MATLAB code. Custom software then  translates the fluorescence readout into a table that 
contains the microchamber address, the number of cells in that microchamber, and the copy 
numbers for each molecule assay 
ST6. Calibration curve:  
A useful requirement for applying Surprisal analysis in characterizing the critical transition process is 
the absolute copy number determination from the fluorescence readout. These absolute 
quantification or calibration was performed using SCBC device and under the exact same condition as 
was done with the single-cell proteomic assay described above, except that standard proteins were 
used instead of cells in the single cell chambers. A mixture of standard recombinant proteins (detail 
of the recombinant proteins in Supplementary table S1) for all the proteins in the assay panel was 
serially diluted in 1× PBS and flowed into the SCBC microchannels. Fluorescence readouts from 
different protein concentration was used to generate the calibration curves. Since the volume of 
microchambers are known, the calibration plot enables to determine the relation between 
fluorescence intensity and the absolute copy number of the protein being assayed, under the 
assumption that the recombinant proteins have same physical and chemical attributes, compared to 
their counterparts in the actual cell. 
ST7. Absolute protein copy-number quantification:  
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The SCBC data is based on fluorescence units, and in order to covert the fluorescence measure to 
absolute protein copy number, the calibration plots were used (Figure 1). To fit the calibration data, 
five parameter regression function was used. 
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Where, 1A , is the estimated response at zero concentration; 2A , is the estimated response at 
infinite concentration; p, slope factor of the response curve; q, asymmetry factor and 0x , mid-range 
concentration value. Statistical output from the single cell analysis is the input for the theory as a 
series of tables, one table per time point for each carcinogen used.  Each column represents a 
measured protein level, while each row represents an individual cell.   
Error Consideration: Error analysis related to Single cell proteomic measurement in SCBC has been 
extensively considered and discussed in previous works
1
. Briefly, it was previously shown that the 
location of a cell within a microchamber does not significantly contribute towards the measurement 
error. Furthermore, it was also demonstrated that the variation of the protein level is dominated by 
biological noise (cell-to-cell heterogeneity) rather than the experimental noise 
[2]
 and that the 
experimental error in measuring the level of a given protein is typically <10%. 
ST8. Cell Lines and Reagents: MCF10F cell line (ATCC) was maintained and passaged in complete 
growth medium (1:1 mixture of DMEM and HAM’s F12 and 5% horse serum. The medium is 
supplemented with mitogenic factor such as: 20ng/ml of epidermal growth factor, 500 ng/ml 
Hydrocortisone, 100ng/ml of Cholera Toxin, 10µg/ml of insulin.) as described elsewhere.
[3]
 Cell 
culture medium was also supplemented with 100 U/ml penicillin and 100µg/ml of streptomycin and 
was maintained in 5% CO2 at 37
0
C. Aqueous stock solution of Benzo(a)pyrene (B[a]P) was prepared  
in dimthysulfoxide (DMSO). 1µM carcinogen dosage medium was prepared by dosing the respective 
stock solutions of the carcinogen in the growth medium. 
ST9. Inducing carcinogenesis: As shown in Fig. 1 of the article, carcinogen treatment comprised of 
three treatment cycles: 24 hrs after splitting the cells into fresh growth medium, the growth medium 
along with the unattached cells are removed and replaced with the medium containing carcinogen. 
48 hours post exposure, carcinogen dosed medium was replaced with fresh medium. The gap 
between successive exposures was 14 days. All the samples were passaged regularly at 3-4 days 
interval. All along the treatment and post-treatment, the cells were maintained in 5% CO2 at 37
0
C. 
After the exposure of the cells to carcinogens, phenotypic assays were performed to detect the 
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acquiring of cancer related properties in cells that survived the carcinogen treatment: Colonogenic 
assay for estimating the proliferative capacity under limited dilution, reduced dependence on growth 
factors and anchorage independent growth.  
ST10. Colonogenic assays: 
Colonogenic assay in normal growth medium: This assay is a conventional method used to study the 
cyto-toxicity and proliferative capacity of mammalian cells growing in monolayer, attached to a 
surface
[4]
 After the cell-split ~5000 cells were seeded into plates with complete growth medium. 
Control cells which haven’t yet undergone carcinogenic transformation have relatively poor colony 
forming efficiency. Cells were maintained at 5% CO2 at 37
0
C incubation. After 8-days of incubation, 
colonies having size >100µm was quantified. Colony counting and image analysis was performed 
using ImageJ (NIH, Bathesda). 
Colonogenic assay for reduced dependence on growth factor : After splitting the cells, ~20,000 cells 
were seeded into plates containing low-mitogen (LM) medium (1:1 mixture of DMEM/F12, 2ng/ml 
cholera endotoxin, 200ng/ml insulin, 10ng/ml hydrocortisol, 0.4 ng/ml EGF and 0.1% horse serum) 
containing reduced serum and mitotic additives to 2% (v/v) of the concentration formulated in the 
complete growth medium.
[5]
 Cells were maintained at 5% CO2 at 37
0
C incubation. Growing cell 
colonies that reached a diameter of > 20µm in LM medium after 10 days of seeding, were identified 
as clones acquiring reduced dependence on growth factor. Colony counting and image analysis was 
performed using ImageJ (NIH, Bathesda). 
Colonogenic Assay for Anchorage independence: Base layer consisted of 2% low-gelling Select 
agarose (Invitrogen) in complete growth medium. Middle layer comprised of 0.5% agarose in a 
mixture of complete growth medium, warmed to ~37
0
C, was seeded with ~20,000 cells per well and 
this was poured on to well-set bottom agarose layer.
[5]
 The middle gel layer was also allowed to 
solidify at 37
0
C. After which, fresh growth medium was topped up on the middle layer. Soft-agar 
cultures were maintained at 5% CO2 at 37
0
C. Colony formation and growth was observed 
microscopically and the cultures were incubated at 37
0
C for 21 days. Fresh media was supplemented 
at a regular interval of ~3 days. After 21 days in culture, colonies having size >50µm was quantified. 
Colony counting and image analysis was performed using ImageJ (NIH, Bathesda). In all the 
colonogenic assays, the colonies were stained with crystal violet prior to counting. 
ST11. Surprisal analysis: 
An early application to average transcription levels and functional proteins is presented in 
[6-10]
. It is 
extended in this article to quantify the changes of protein copy numbers in individual cells. In such an 
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approach each sampled cell is regarded as a typical representative of a large number of cells from the 
bulk culture.  
We assume that cellular non-equilibrium system is in a state of maximal entropy subject to 
constraints at every time point during the processes of carcinogenesis. The state of the maximal 
entropy in biological cells is the steady state, a state without any constraints on the biological 
networks. Biological steady state is a state in which an internal biological process is maintained at 
a relatively constant level and intermediates are formed and consumed at equal rates.
[11]
 For 
experiments at constant temperature (such as 37
0
, typical in biology), an entropy maximum is 
equivalent to a free energy minimum, and the state of lowest free energy is the steady state.  The 
constraints are detected and quantified by identifying how the protein expression levels respond to 
those constraints.  For each measured proteins the extent of participation of the protein in the 
biological process responding to constraints is defined. 
The experimentally determined values, ( , )X cell ti , of the functional proteins in every cell as a 
function of time are used to identify the constraints. Constraints prevent the entropy from reaching 
the global possible maximum, and thereby generate deviations from the steady state. We seek to 
define the protein concentrations in every cell , ( , )oX cell ti  at the steady state-the state in order to 
build protein distributions at the biological global maximum of the entropy-and compare it to the 
experimental protein level distributions. 
At every time point in course of carcinogen treatment the most stable state is the state of minimal 
free energy while deviations thereof necessarily have a higher free energy. We characterize the 
expression levels of proteins at a given point in time we use surprisal analysis as summarized in 
Equation (1) of the main text.  
To obtain Equation (1) in the main text, we relate protein concentrations to the chemical potential 
(under constant temperature and pressure) using the fundamental physical chemical relations:
[12]
        
            (2)
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The equations above relate the experimental expression level of protein i to its value in the steady 
state: 
ln ( , ) ln ( , ) ( ) /i i io oX cell t X cell t kTi µ µ= + −         (3) 
Given the experimental data ( ,iX cell t ), which is the measured copy number of protein i in a given 
cell at time, we seek to obtain ( , )oX cell ti , which is the functional protein expression expected at 
the steady state, as well as ( ) /i io kTµ µ− , which is the deviation from the steady state. Equation 
(3) represents the changes in the chemical potential for each measured protein. From it we can get 
the change in the free energy of the system as a whole when the constraint(s) are relaxed, 
(
 
∆G = X i (cell,t)i∑ (µi − µio) ≠ 0 ).  To calculate the steady state expression levels, ( , )oX cell ti , 
and deviations thereof, 
 
(µi − µio ) / kT , we use a procedure described in [9]. Briefly surprisal analysis 
equates a representation of the data as a sum of terms (right hand side of Equation (1) in the main 
text) to the logarithm of the measured expression level of protein i in the cell c at the time t, 
( , )X cell ti . This is repeated for every cell at every time point t. SVD is used as a mathematical tool 
to determine the two sets of parameters that are needed in surprisal analysis: the cell dependent 
weights of the constraints ( , )cell tλα  (Lagrange multipliers), and the participation of each individual 
protein i in the specific constraint, Giα . Determination of the errors for the calculated parameters 
was performed as described previously.
[13]
 In the numerical procedure we represent the steady state 
level as 
 
Xi
o(cell,t) = exp −Gi0λ0(cell,t)( ) .[6, 9] ( , )0 cell tλ  represents the weight of the steady state 
term in every measured cell. The weight of the proteins when all cellular processes are balanced are 
described by 0Gi . In the present study we analysed the expression levels of phosphorylated 
(activated) enzymes and other functional proteins, the levels of which are expected to be sensitive to 
the carcinogen perturbations, and thus change with time.  The deviations from the steady state are 
the terms labelled as 1,2α =  in the order of their decreasing weight as given by 
 
λα (cell,t) . The 
contribution of each protein to a given unbalanced process λα , is given by 
 
Giα . Thus a change in 
the chemical potential of protein i, ( ) /oi i kTµ µ− , due to the constraints 1,2...α =  is represented 
by ( , )1G cell ti λα α α∑ = . 
[7-9]
 When the steady state term and all the constraints are kept in the 
exponent in Eq. (1) in the main text, it provides a numerically exact representation of the data and is 
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not an approximation. Typically however the sum over α  in the exponent is truncated to include 
only the few significant terms. For more details see 
[7-9]
. 
ST12. Identification of the phase co-existence using Surprisal analysis. 
Surprisal analysis can, in principle, use the measured intensities of 11 proteins to identify up to 10 
constraints that deviate the system from its stable state. The analysis shows that only the first two 
constraints α =1,2  are significant, and the second significant process, 	α = 2, contributes only to 
day 8 (Figure 3a). The transition as seen most clearly in days 12 and 21, is dominated by the first 
process, 	α =1 (Figure 3b). To unmask any possible cell individuality, we show the weight 1( , )cell tλ  
of the process α = 1 in every cell at each measured time point t(Figure 3a). To further emphasize the 
change in value of 1( , )cell tλ  due to the transition, scatter plots of ( , )0 cell tλ  vs. ( , )1 cell tλ  for 
days 12 and 28 are shown (Figure 3c). It shows that the two cell populations differ markedly in the 
values of 1( , )cell tλ . A key point of surprisal analysis is that the weights of the constraints, the 
 
λα (cell,t) ’s, are common to all the 11 proteins. However, the weight of the contribution of each 
protein to any constraint 	α =1,2,.. is different (Figure S7). 	
G
iα  is the weight (= importance) of 
protein i in the process α , identifying which proteins are most influencing/most influenced by this 
constraint. Surprisal analysis determines 
	
G
iα  to have the same value at all times. The change in the 
protein levels is dictated by the weights of the processes 1,2...,α = . 
ST13. The response function :  
Using entropy not as a statistical measure of dispersion but as a physical quantity, we apply an 
approach using the covariance matrix as a response function. For weak perturbations this provides 
an extension of the well-known qualitative principle of Le Chatelier
[2]
 to characterize protein 
fluctuations. For strong perturbations this provides the signature of a phase transition in the course 
of carcinogen treatment. The theory is summarized by the matrix equation .  Here, 
 
∆N
 
is a column vector with 11 components representing change in the average protein levels of the 11 
assayed proteins. β  is 1/kT, where k is Boltzmann’s constant, and T is temperature.  is a 11x11 
matrix of the experimentally measured covariance of a specific protein Pi with another specific 
protein Pj. µ is a column vector whose 11 components describe the change in the chemical 
potentials of 11 proteins, due to a change in external conditions (carcinogen perturbation). To 
characterize the processes of phase transition we perform diagonalization of the  at every time 
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point t and compare primary eigenvalues between different time points to identify a time interval 
where phase transition occurs. 
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2. Supplementary Figures: 
 
 
Figure S1: Details of the SCBC microfluidic platform. a. shows the overall design layout of the of the 
SCBC chip, red channels corresponds to the flow layer and the blue layer to the control channels, 
which is used to manipulate the flow layer. SCBCs has about 300 microchambers, which contains 
approximately 30% single cell and 25% zero cell chambers (for background normalization). b. 
Expanded view of a single-cell chamber in the SCBC device. Details of the cell chamber structure is 
represented by the labelled numerals. Cell/s are trapped in a single channel of the flow channel (1, in 
figure). c. A sample fluorescence readout of the SCBC slide after the completion of the immune-
sandwich assay using Genepix 4400A microarray scanner. Red signals corresponds the actual protein 
measurement and green signals corresponds to the marker. Numbers inside the image represents the 
number of cells that were trapped in the respective single cell chambers. d. descriptive diagram of the 
immuno-sandwich assay used in the SCBC chip for the proteome quantification. e. Calibration plot 
obtained by measuring the fluorescence intensity of different proteins (inset label in the plot) at 
different dilution level. Recombinant proteins were used for the measurements. The plot has a 
sigmoidal shape, similar to the saturation kinetics observed in traditional ELISA assay. 
. 
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Figure S2: Significance of single cell measurements. Measurements of multiple analytes from the 
same single cells yield quantitative analyte-analyte correlations (and anti-correlations). This is a 
uniquely single cell measurement. a. Consider the levels of the three hypothetical phosphoproteins (p-
A, p-B, and p-C) intended to represent a small signaling network within a cell. Stimulation (or 
drugging) of the cell may collectively repress all protein levels as shown in the bulk 
immunoprecipitation assays. b. Single cell analysis presented in the two-dimensional scatter plots 
reveals a deeper picture. Note that in the plots for the undrugged cells, all phosphoprotein levels are 
high, but only p-A and p-B are strongly correlated. Upon drugging, all phosphoproteins are repressed, 
but p-A and p-B are non-correlated, p-C and p-B are strongly correlated, and p-A and p-B are anti-
correlated. c. This inferred correlation network is shown in the network graphic, in which the protein 
levels are indicated by the sizes of the spheres, and the correlations are indicated by the edges.  
Correlation, of course, does not mean causation, but a correlation network generated at the single 
cell level can provide a rich set of testable hypotheses. 
 
Figure S3: Phenotypic characterization of increase in proliferative capacity of carcinogen treated 
MCF-10F as a function of time. Results of colonogenic assay of cells treated with BaP, to determine 
dependence on mitotic growth factor. The cell were grown in medium having reduced growth factor. 
At day 96, there is a stark increase in proliferative capacity of cells treated with carcinogen in low 
growth factor medium. 
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Figure S4: Results of SCBC analysis of control samples. a. Protein-protein covariance matrices, 
extracted from SCBC data of MCF-10F control cells passaged regularly, at three different time points. 
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b. One-dimensional scatter plots of the single cell levels of all the proteins in the panel, at the 
corresponding time points of the control samples. 
 
Figure S5: Scatter plot of protein panels analysed using the SCBC platform. Variations (distribution) 
represented by 1D scatter plot for the remaining proteins used in this work, measured at different 
time points during and post treatment of MCF-10F cells with BaP. There is a significant increase of 
variations in copy numbers for most proteins during the transition window of 8-28 days 
   
 
Figure S6:  Constraint 3α =  in B[a]P treated cells. Constraint 3α =  is identified using Surprisal 
analysis and its amplitude, ( , )3 c tλ , is shown for all single cells as a function of time. The black lines 
are error limits due to noise in the data. 
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Figure S7: Extents of participation of the assayed proteins in the steady state and unbalanced 
processes. Surprisal analysis yields the extent of participation of each assayed protein, Giα , in the 
biological processes described by constraints 0α =  (the steady state) and 1,2,3α =  in the B[a]P 
treated cell population.  
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3. Supplementary Table: 
Table S1: List of DNA oligoneucleotides and Antibody pairs used for the SCBC 
Immunoassays used in this work. All oligonucleotides were synthesized by Integrated DNA 
Technology (IDT) and purified via high performance liquid chromatography (HPLC). 
DNA DNA Sequence   
C AAAAAAAAAAAAAGCACTCGTCTACTATCGCTA   
C' /5AmMC6/AAAAAAAAAAAAATAGCGATAGTAGACGAGTGC   
D AAAAAAAAAAAAAATGGTCGAGATGTCAGAGTA   
D' /5AmMC6/AAAAAAAAAAAAATACTCTGACATCTCGACCAT   
E AAAAAAAAAAAAAATGTGAAGTGGCAGTATCTA   
E' /5AmMC6/AAAAAAAAAAAAATAGATACTGCCACTTCACAT   
F AAAAAAAAAAAAAATCAGGTAAGGTTCACGGTA   
F' /5AmMC6/AAAAAAAAAAAAATACCGTGAACCTTACCTGAT   
G AAAAAAAAAAAAAGAGTAGCCTTCCCGAGCATT   
G' /5AmMC6/AAAAAAAAAAAAAAATGCTCGGGAAGGCTACTC   
H AAAAAAAAAAAAAATTGACCAAACTGCGGTGCG   
H' /5AmMC6/AAAAAAAAAAAAACGCACCGCAGTTTGGTCAAT   
I AAAAAAAAAAAAATGCCCTATTGTTGCGTCGGA   
I' /5AmMC6/AAAAAAAAAAAAATCCGACGCAACAATAGGGCA   
J AAAAAAAAAAAAATCTTCTAGTTGTCGAGCAGG   
J' /5AmMC6/AAAAAAAAAAAAACCTGCTCGACAACTAGAAGA   
K AAAAAAAAAAAAATAATCTAATTCTGGTCGCGG   
K' /5AmMC6/AAAAAAAAAAAAACCGCGACCAGAATTAGATTA   
L AAAAAAAAAAAAAGTGATTAAGTCTGCTTCGGC   
L' /5AmMC6/AAAAAAAAAAAAAGCCGAAGCAGACTTAATCAC   
M AAAAAAAAAAAAAGTCGAGGATTCTGAACCTGT   
M'-Cy3 /5Cy3/AAAAAAAAAAAAAACAGGTTCAGAATCCTCGAC   
N AAAAAAAAAAAAAGTCCTCGCTTCGTCTATGAG   
N' /5AmMC6/AAAAAAAAAAAAACTCATAGACGAAGCGAGGAC   
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